Tag Archives: funding

← Older posts Newer posts →

Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs

Typically a new biotech assembles a group of investors that collectively puts in the money a fledgling company requires to develop or acquire potential therapies. Engrail Therapeutics, which emerged from stealth Thursday with $32 million in outside financing, landed its entire Series A funding from a sole source: Nan Fung Life Sciences, a subsidiary of […]

Posted in Boston blog main, National blog main, San Diego, San Diego blog main, San Diego top stories, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs

Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer

Lassen Therapeutics, a biotech that is developing antibodies as potential treatments for fibrosis, rare diseases, and cancer, debuted Wednesday with $31 million in Series A financing. The San Diego-based company says it will use the money to accelerate its antibody programs, including asking the FDA for the green light to move its lead drug candidate […]

Posted in Boston blog main, National blog main, San Diego, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer

Reata Bags $350M as It Preps Rare Chronic Kidney Disease Drug for FDA

Reata Pharmaceuticals is readying its lead drug, a potential treatment for a rare, genetic form of chronic kidney disease called Alport syndrome, for an FDA filing this year. New York private equity giant Blackstone Group, via its newly flush life sciences investment arm, is betting $350 million that the treatment will be a big seller […]

Posted in National blog main, National top stories, New York blog main, New York top stories, Texas, Texas blog main, Texas top stories | Tagged , , , , , , , , , , , , | Comments Off on Reata Bags $350M as It Preps Rare Chronic Kidney Disease Drug for FDA

Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs

Another venture capital firm that backs biotechs has raised a multimillion-dollar fund—money the firm, Cambridge, MA-based Atlas Venture, says it will use to continue creating and funding companies that are creating new medicines. Atlas revealed Friday that it closed its 12th fund after raising $400 million, a total that pushes the amount the company has […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories | Tagged , , , , , , , , , , , , , , , , , , | Comments Off on Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs

Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More

A year ago about 40,000 people gathered in Chicago for the annual meeting of the American Society of Clinical Oncology. Today a virtual version of the ASCO conference, the cancer field’s largest, kicks off, with oncologists and others tuning in from throughout the country and around the world to check out the latest in cancer […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More

At Rome Therapeutics, Kapeller Aims to Turn “Junk” Into New Drugs

A new biotech, Rome Therapeutics, launched Monday with $50 million and a plan to develop novel drugs based on new insights into repeats in the non-coding stretches of the human genome. Rome’s debut pulls back the curtain on what Rosana Kapeller, the company’s co-founder and CEO, has been up to since she left Nimbus Therapeutics […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , | Comments Off on At Rome Therapeutics, Kapeller Aims to Turn “Junk” Into New Drugs

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Sciences has signed an agreement with South San Francisco biotech Second Genome to use its microbiome drug development expertise to advance the compounds it is evaluating in inflammatory disease and to identify new ones. “There is a growing body of evidence that the microbiome plays an important role in disease progression and treatment response […]

Posted in National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , | Comments Off on Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

VenBio Partners Bags $394M to Back More Medicine-Making Biotechs

Investors worried about a recession like venBio Partners’ risk-mitigated approach to venture capital investing. That approach has led new limited partners to join earlier backers in putting nearly $400 million into the San Francisco-based firm’s new fund. VenBio announced Friday it closed its third fund, raising $394 million which it plans to invest using the […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , , , , , , , , , , , | Comments Off on VenBio Partners Bags $394M to Back More Medicine-Making Biotechs

Flagship Adds $1.1B for New Meds, More AI, & “Health Security”

Flagship Pioneering founder and CEO Noubar Afeyan didn’t know a global pandemic was in the cards for 2020 when he and his team laid out three new thematic areas of focus for the company last fall. One proved eerily prescient: The notion of “health security,” or the development of new products and therapies to treat […]

Posted in Boston blog main, Boston top stories, National, National blog main, National top stories, San Diego blog main, San Francisco blog main, Seattle blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Flagship Adds $1.1B for New Meds, More AI, & “Health Security”

Aspen Neuro Adds $70M to Test Parkinson’s Cell Therapy in the Clinic

Parkinson’s disease patients experience progressive breakdown of their neurons, cells essential to movement and mental function. Aspen Neuroscience, a biotech working to develop a therapy that would reprogram those patients’ own living cells in ways that would allow the cells to reconstruct their damaged neural networks, has raised $70 million in a Series A financing […]

Posted in National blog main, New York blog main, San Diego, San Diego blog main, San Diego top stories, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Aspen Neuro Adds $70M to Test Parkinson’s Cell Therapy in the Clinic← Older posts Newer posts →